Medical News |
- Central BP thresholds proposed
- Sleep dysfunction increased in Asian GERD patients
- Central BP thresholds proposed
- Pneumococcal serotypes linked to respiratory failure risk
- Pemetrexed–bevacizumab effective maintenance therapy for NSCLC
- <i>ROS1</i> rearrangement ‘specific for lung cancer in never-smokers’
- Pemetrexed–bevacizumab effective maintenance therapy for NSCLC
- <i>ROS1</i> rearrangement ‘specific for lung cancer in never-smokers’
- Cytoreductive nephrectomy for small RCC tumors questioned
- Data support 2011 GOLD classifications
- IC/BPS work loss ‘needs attention’
- Cytoreductive nephrectomy for small RCC tumors questioned
| Central BP thresholds proposed Posted: 28 Jul 2013 05:00 PM PDT Central blood pressure edges closer to clinical use with the establishment of a threshold predictive for cardiovascular mortality. |
| Sleep dysfunction increased in Asian GERD patients Posted: 28 Jul 2013 05:00 PM PDT Sleep dysfunction is common in Korean patients with gastroesophageal reflux disease, researchers have found. |
| Central BP thresholds proposed Posted: 28 Jul 2013 05:00 PM PDT Central blood pressure edges closer to clinical use with the establishment of a threshold predictive for cardiovascular mortality. |
| Pneumococcal serotypes linked to respiratory failure risk Posted: 28 Jul 2013 05:00 PM PDT A large observational study shows that pneumococcal serotype is a major determinant of respiratory failure in patients with invasive pneumococcal pneumonia. |
| Pemetrexed–bevacizumab effective maintenance therapy for NSCLC Posted: 28 Jul 2013 05:00 PM PDT Pemetrexed in combination with bevacizumab is superior to bevacizumab alone when given as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer, results of the AVAPERL trial show. |
| <i>ROS1</i> rearrangement ‘specific for lung cancer in never-smokers’ Posted: 28 Jul 2013 05:00 PM PDT Lung adenocarcinomas harboring genetic rearrangements of the receptor tyrosine kinase proto-oncogene ROS1 are more frequent in people who have never smoked than in smokers, a study by South Korean researchers shows. |
| Pemetrexed–bevacizumab effective maintenance therapy for NSCLC Posted: 28 Jul 2013 05:00 PM PDT Pemetrexed in combination with bevacizumab is superior to bevacizumab alone when given as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer, results of the AVAPERL trial show. |
| <i>ROS1</i> rearrangement ‘specific for lung cancer in never-smokers’ Posted: 28 Jul 2013 05:00 PM PDT Lung adenocarcinomas harboring genetic rearrangements of the receptor tyrosine kinase proto-oncogene ROS1 are more frequent in people who have never smoked than in smokers, a study by South Korean researchers shows. |
| Cytoreductive nephrectomy for small RCC tumors questioned Posted: 28 Jul 2013 05:00 PM PDT Researchers have found that cytoreductive radiofrequency ablation plus sunitinib offers limited benefits over sunitinib alone in the treatment of small tumors in patients with metastatic renal cell carcinoma. |
| Data support 2011 GOLD classifications Posted: 28 Jul 2013 05:00 PM PDT Researchers have found support for the multifactorial approach advocated by the 2011 Global Initiative for Chronic Obstructive Lung Disease guidelines using over airflow limitation alone to classify patients with chronic obstructive pulmonary disease. |
| IC/BPS work loss ‘needs attention’ Posted: 28 Jul 2013 05:00 PM PDT Researchers say that more attention is needed to the detrimental impact of interstitial cystitis/bladder pain syndrome on women's ability to work. |
| Cytoreductive nephrectomy for small RCC tumors questioned Posted: 28 Jul 2013 05:00 PM PDT Researchers have found that cytoreductive radiofrequency ablation plus sunitinib offers limited benefits over sunitinib alone in the treatment of small tumors in patients with metastatic renal cell carcinoma. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment